

Heroic Limb
Salvage Strategies:
Peroneal Blind
Distal Bypasses

Jorge Rey, MD



## Disclosures

• None

## Contents

- 1. Lower extrem ity occlusive disease
- 2. Peroneal artery bypass
- 3. Peroneal artery classification
- 4. Methods
- 5. Results
- 6. Conclusions

# Lower Extremity Arterial Disease

#### Ep id em io logy

- □ PAD affects 12%-20% of the population older than 60 years old in the US. (1)
- □ Represents equal morbidity, mortality and economic burden to healthcare system than coronary heart disease and stroke. (2)
- □ Symptoms vary from intermittent claudication to critical limb ischemia (CLI) depending on severity and location of the lesion. (3)
- ☐ An extrem ity with CLI has 40% risk of am putation at 6 m on the after diagnosis and one-year mortality of 20-30%. (3)
- □ CLI occurs in <10 % of all PAD patients. (4)


Firnhaber, J. M., & Powell, C. S. (2019). Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. American family physician.

<sup>2.</sup> Peripheral arterial disease. Am erican Heart Society. 2012.

<sup>3.</sup> Rutherford's vascular surgery. 7th edition

<sup>4.</sup> TASCII, J Vasc Surg. 2007

## Pathophysiology and risk factors



- ✓ >65 yo: 1.5x risk for every decade
- ✓ Hypertension: 2.5x risk in men and 3.9x in women
- ✓ Diabetes mellitus: for every 1% increase in AlC, increase 28% the risk of PAD
- ✓ Hyperlip idem ia
- ✓ Sm oking
- ✓ Hom ocysteinem ia

- l. Cronenwett & Johnston. Chapter 104: lower extremity arterial disease. Rutherford's Vascular Surgery. Society for Vascular Surgery. 7th Edition, Vol2.
- 2. National Health and Nutrition Examination Survey.

## Management

- ☐ Lifestyle changes
- ☐ Exercise therapy
- ☐ Medical optim ization: statins, antiplatelet, hypertension and diabetes control
- ☐ Pharm acological treatments for claudication:
  - ✓ Pentoxifylline (Trental): first FDA approved
  - ✓ Cilostazol (Pletal): FDA approved
- Revascularization indicated in:
  - ✓ Life lim iting claudication
  - ✓ Rest pain
  - ✓ Tissue loss: non-healing ulcers or gangrene
- 1. Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. Catheter Cardiovasc Interv. 2015 Oct;86(4):611-25. doi: 10.1002/ccd.26122. Epub 2015 Aug 10. PMID: 26256456.
- 2. Cronenwett & Johnston. Chapter 104: lower extremity arterial disease. Rutherford's Vascular Surgery. Society for Vascular Surgery. 7th Edition, Vol2.

#### Revascularization

- □ Surgical revascularization is the standard treatment for CLI secondary to femoropopliteal disease, and a lim b salvage measure for infrapopliteal disease. (1)
- □ Endovascular approach: preferred as initial therapy. Less invasive and proved equality in am putation-free survival compared to bypass. (2)
- □ Bypass surgery: performed in complex, extensive lesions, when patient has more than 2-year estimated survival. Shown to have improved patency. (2)

\*Maxim izing forefoot reperfusion is key for lim b salvage.



**FIG. 23-59.** A high-resolution computed tomography angiography of a patient with normal right lower extremity arterial circulation. Distal occlusive disease is noted in the left tibial arteries (*arrow*).

<sup>1.</sup> JaffMR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. Catheter Cardiovasc Interv. 2015.

<sup>2.</sup> Mohapatra, A., Boitet, A., Malak, O., Henry, J. C., Avgerinos, E. D., Makaroun, M. S., Hager, E. S., & Chaer, R. A. (2019). Peroneal bypass versus endovascular peroneal intervention for critical limb ischem ia. Journal of vascular surgery.


#### Considerations for bypass

- □ Determ in e:
  - ✓ In flow vessel
  - ✓ Outflow vessel (Target vessel)
  - ✓ Type and quality of the conduit

## Peroneal Artery Bypass Surgery

#### Evidence for peroneal bypass

- ☐ Choose the most proximal non-diseased segments of the peroneal artery as outflow if it has direct continuity to the foot.
- Peroneal artery bypass is a durable procedure when the peroneal artery is the least diseased vessel at the infrageniculate level.
- ☐ Advantages:
  - ✓ Peroneal artery is often spared of atherosclerotic disease compared to other distal vessels.
  - ✓ Peroneal artery has rich collaterals to the anterior and posterior circulation of the foot.
  - ✓ Requires shorter segment of vein/graft compared to pedal bypass.
  - ✓ Avoid perform ing incision on the foot, which is more prone to infections and delayed healing.




4.68 Arteries of right lower extremity, posterior view (schematic drawing).

<sup>1.</sup> Mohapatra, A., Boitet, A., Malak, O., Henry, J. C., Avgerinos, E. D., Makaroun, M. S., Hager, E. S., & Chaer, R. A. (2019). Peroneal bypass versus endovascular peroneal intervention for critical limb ischemia. Journal of vascular surgery.

<sup>2.</sup> Edward J. Plecha, Gary R. Seabrook, Dennis F. Bandyk, Jonathan B. Towne. (1993). Determinants of successful peroneal artery bypass, Journal of Vascular Surgery, Volume 17, Issue 1. Pages 97-106. ISSN 0741-5214.

<sup>3.</sup> Rutherford's Vascular Surgery. 7th Edition

## Peroneal Artery Classification







Type A: anterior and posterior branches.




Type B: anterior branches only




Type C: posterior branches only





Type D:
poor/diseased distal
branches



Type E: Isolate/blind segment



Type F:
No peroneal artery
visible

Can we achieve lim b-salvage using a blind or diseased peroneal artery as outflow vessel for a bypass procedure?

#### Methods

Retrospective chart review at University of Miam i and Jackson Memorial Hospital for the past 10 years (2012-2022)

Inclusion/Exclusion criteria

- >18 years
- CPT codes including all tibial artery bypass

509

70

 Filtered bypass procedures to peroneal artery as an outflow.  Peroneal artery classification D, E, F per angiogram

32

#### Methods

#### Outcomes

- Lim b salvage at 1 year
- Reintervention at 1 year
- Readmission rates
- Clin ical im provement
- □Prim ary patency rates
- □ Secondary patency rates
- □Pero-operative complications



## Blind peroneal artery

	Good Outflow n=38 (54%)	Blind Outflow n=32 (46%)		
A	12 (31.5%)	D	18 (56%)	
В	12 (3 1.5%)	E	9 (28%)	
C	14 (37%)	F	5 (16%)	

## Surgical characteristics

	A-B-C	D-E-F	P-value
	n=38	n=32	
In flow Vessel-N (%)			0.56
External iliac artery	2 (5%)	0 (0%)	
Common femoral artery	13 (34%)	15 (47%)	
Superficial femoral artery	7 (18%)	5 (16%)	
Profunda artery	2 (5%)	0 (0%)	
Above the knee popliteal artery	6 (17%)	9 (28%)	
Below the knee popliteal artery	5 (14%)	3 (9%)	
Previous bypass	2 (5%)	0 (0%)	
Proxim al peroneal	1 (2%)	0 (0%)	
Conduit - N (%)			0.27
In situ	9 (24%)	3 (9%)	
Autogenous	22 (58%)	21(66%)	
Non-autogenous	7 (18%)	8 (25%)	

#### A-B-C Vs. D-E-F

#### Demographic characteristics

	A-B-C n=38	D-E-F n=32	P-value
Age – in years (SD)	67.3 (±10.39)	65.13 (±17.44)	0.53
Sex - N (%)			0.66
Fem ale	15 (39.5%)	11 (34.4%)	
Male	23 (60.5%)	21(65.6%)	
Ethnicity – $N$ (%)			0.015
Caucasian	5 (13%)	14 (44%)	
Hispanic	24 (63%)	12 (37%)	
African American	9 (24%)	6 (19%)	
Body mass index $-kg/m^2$ (SD)	$27.52 (\pm 5.7)$	$27.14 \ (\pm 7.26)$	0.81
Smoking - N(%)			0.44
Never	11 (29%)	11 (36%)	
Form er	17 (45%)	10 (32%)	
Current	10 (26%)	10 (32%)	
Indication for Bypass – N (%)			
Rest pain	9 (24%)	5 (16%)	0.81
Tissue loss	15 (39%)	6 (19%)	0.05
Acute limb ischemia	14 (37%)	21 (65%)	0.016

	A-B-C	D-E-F	P-value
	n=27	n=22	
Com orbidities – N (%)			
Hypertension	34 (89%)	25 (78%)	0.19
Diabetes Mellitus	22 (58%)	18 (56%)	0.23
Hyperlip id e m ia	14 (37%)	12 (37%)	0.95
Coronary Arterial Disease	16 (42%)	11 (34%)	0.51
Congestive Heart Failure	4 (10%)	2 (6%)	0.52
Asthma/COPD	9 (24%)	2 (6%)	0.05
Hypercoagulability	2 (5%)	5 (15%)	0.150
Active Malignancy	4 (10%)	3 (9%)	0.87
Atrial Fibrillation	6 (16%)	4 (12%)	0.69
Chronic Kidney Disease	6 (16%)	4 (12%)	0.28
TIA/Stroke	0 (0%)	8 (25%)	0.001
Im m unosuppression	1 (3%)	3 (9%)	0.23
HIV	4 (10%)	1 (3%)	0.23
Vasculitis	1 (3%)	0 (0%)	0.35
Pre-op medications -N (%)	, ,	, , ,	
Aspirin	22 (58%)	13 (4 1%)	0.15
Plavix	18 (47%)	11 (34%)	0.27
Brilinta	0 (0%)	1 (3%)	0.27
Coum ad in	1 (3%)	3 (9%)	0.23
Eliq u is	8 (21%)	5 (16%)	0.56
Xarelto	2 (5%)	2 (6%)	0.85
Heparin	3 (8%)	0 (0%)	0.10
Cilostazol	2 (5%)	1(3%)	0.70
Previous vascular intervention - N (%)	30 (79%)	20 (62.5%)	0.79
Open	7 (23%)	6 (20%)	
Endovascular	8 (26%)	4 (30%)	
Hybrid	15 (50%)	10 (50%)	

#### Readmissions

- ■Worsening and infection of foot ulcers (most common)
- □Surgical site in fection
- □Cellulitis on the extremity
- □ Acute lim b ischem ia
- □ Gan grene
- Unrem itting pain in the extrem ity
- □ Ble e d in g
- □ AV fistu la
- ☐Groin pseudoaneurysm



	A-B-C n=38	D-E-F n=32	P-value
Early complications - N (%)			
Occlusion of the bypass	3 (8%)	9 (28%)	0.12
Bypass reoperation	4 (10%)	3 (9%)	0.12
Bleeding	2 (5%)	3 (9%)	0.50
Compartment syndrom e	0 (0%)	6 (19%)	0.054
Wound dehiscence	3 (8%)	3 (9%)	0.79
Late complications - N (%)			
SSI	6 (16%)	5 (16%)	0.13
Persistent edem a	4 (10%)	1(3%)	0.23
Arteriovenous fistula	1 (2%)	1(3%)	0.9
Thrombosis of the bypass	O (O%)	4 (12%)	0.023
Amputations – N (%)	4 (10%)	11 (34%)	0.06
Amputation-free survival time – median in days [IQR]	228 [4-10 19]	32 [4-87]	0.049
Readmission -N (%)	19 (53%)	16 (52%)	0.92
Time to hospital readmission – median in days [IQR]	47 [20-93]	37 [25-86]	0 .4 5
90-day mortality – N (%)	2 (5%)	0 (0%)	0.27

## Patency

	A-B-C	D-E-F	P-value
	n=27	n=22	
Primary patency – N (%)	20 (52%)	14 (43%)	0.46
Secondary patency – N (%)	25 (66%)	19 (59%)	0.58

### Lim b Salvage

	A-B-C n=38	D-E-F n=32	P-value
30-day clinical improvement - N (%)	26 (68%)	22 (68%)	0.78
30-day reintervention -N (%)	11 (3 1.4 %)	16 (53.3%)	0.74
1-year reintervention – N (%)	13 (36%)	18 (58%)	0.014
1-year lim b salvage – N (%)	28 (78%)	21(68%)	0.087

#### Associations

- Fem ale gender patients had higher risk of readmission (5.5 [1.21-25.6]; p=0.027), as well as African American race/ethnicity (10.38 [1.3-82]; p=0.027)
- □Non-autogenous bypass conduit was associated with lower secondary patency rates (0.08 [0.009-0.7]; p=0.031)
- Blind peroneal arteries (classification D, E, F) had higher risk of am putation (7.17 [1.33-38.55]; p=0.022) and 1-year reintervention (3.88 [1.08-13.8]; p=0.037)

#### Take-home messages

- When no suitable target vessel is identified through angiogram, selective exploration of distal arteries with flow detected intraoperatively may be a feasible strategy to find an adequate outflow to restore vascularization to the foot.
- ☐ More aggressive revascularization measures lead to higher chances of lim b salvage.
- More evidence is needed to classify the peroneal artery and determ in especific scenarios where this strategy is more successful for lim b salvage.







Thank you